Emergent BioSolutions Inc. (LON:0IGA)
9.90
+0.26 (2.70%)
At close: Oct 24, 2025
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $140.90M USD in the quarter ending June 30, 2025, a decrease of -44.68%. This brings the company's revenue in the last twelve months to $851.60M, down -22.74% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.
Revenue (ttm)
$851.60M
Revenue Growth
-22.74%
P/S Ratio
0.62
Revenue / Employee
$946.22K
Employees
900
Market Cap
387.81M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Emergent BioSolutions News
- 11 days ago - Emergent BioSolutions EVP Sold $306K In Company Stock - Benzinga
- 21 days ago - Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions (EBS) Lands $29M International Supply Agreement - GuruFocus
- 5 weeks ago - Emergent BioSolutions (EBS) Lands $29 Million Government Contract - GuruFocus
- 5 weeks ago - Emergent Biosolutions secures $29M in MCM product orders from international government partner - Seeking Alpha
- 5 weeks ago - Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Wins $17 Million BARDA Contract To Supply Tembexa Oral Suspension - Nasdaq